Structured evidence table for Nicotinamide Riboside Pterostilbene Menopause Transition Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nicotinamide Riboside Pterostilbene Menopause Transition Randomized Trial | Therapeutic strategies targeting aging hallmarks can delay aging and mitigate disease risk. | 4 | Dong R (2026) | Insights into the therapeutic strategies for aging and aging-associated diseases. |
| Nicotinamide Riboside Pterostilbene Menopause Transition Randomized Trial | Recent advances have focused on three strategies: senolytics (eliminating senescent cells, e.g., dasatinib + quercetin), senomorphics (inhibiting the senescence-associated secretory phenotype, e.g., rapamycin), and senoreversion (rejuvenating senescent cells via epigenetic reprogramming). | 4 | Dong R (2026) | Insights into the therapeutic strategies for aging and aging-associated diseases. |
| Nicotinamide Riboside Pterostilbene Menopause Transition Randomized Trial | The convergence of AI, multitarget strategies, and precision medicine signals a transformative era in extending healthspan and combating aging-associated diseases. | 4 | Dong R (2026) | Insights into the therapeutic strategies for aging and aging-associated diseases. |
| Nicotinamide Riboside Pterostilbene Menopause Transition Randomized Trial | Aging is a complex biological process characterized by progressive functional decline, driving the incidence of age-related diseases such as neurodegeneration, metabolic disorders, and cardiovascular diseases. | 4 | Dong R (2026) | Insights into the therapeutic strategies for aging and aging-associated diseases. |
Source documents